Summary: CAR-T cell therapy — previously used exclusively for blood cancers — is now being applied to severe autoimmune diseases in China, with Chinese institutions leading the world in both published results and patient volume. For refractory lupus, inflammatory myopathy, and other autoimmune conditions that have failed standard treatment, China’s CAR-T programs represent the most clinically advanced body of evidence available globally. This guide explains the science, which conditions are being treated, who qualifies, what the treatment involves, and what the published outcomes show. This is an educational overview, not an enrollment pathway — every autoimmune CAR-T trial in China is run by a public academic hospital, and eligibility can only be determined by that hospital’s own investigators after an in-person evaluation. There is no remote or third-party route into these trials.
Key Facts
- A 2023 Chinese cohort published in Lancet Rheumatology (Peking Union Medical College Hospital): 21 patients with refractory SLE; 19/21 achieved SLEDAI score normalization; 16/21 remained off all immunosuppression at 12 months.
- By 2024, Chinese centers had treated more autoimmune CAR-T patients than the rest of the world combined — with no approved product in any country globally.
- CAR-T manufacturing for autoimmune protocols runs 7–21 days, consistent with standard commercial CAR-T timelines; total treatment stay in China is approximately 5–6 weeks including pre-treatment workup, leukapheresis, manufacturing, lymphodepletion, infusion, and monitoring.
- The landmark 2021 Erlangen study (Nature Medicine): 5/5 patients with refractory systemic lupus erythematosus (SLE) achieved drug-free remission maintained at 17-month follow-up.
- A 2024 Chinese cohort in inflammatory myopathy: 13/15 patients with refractory dermatomyositis/polymyositis showed significant improvement; 9/15 achieved complete clinical remission.
- Trial slots are limited and enrollment decisions rest entirely with the treating hospital’s investigators — published response rates describe patients who were already accepted into a trial, not the odds of being accepted into one.
Table of Contents
Why CAR-T Is Now Being Used for Autoimmune Disease
CAR-T cell therapy works by engineering a patient’s own T-cells to recognize and destroy cells carrying a specific surface marker. In cancer, the target is typically a marker on malignant cells — CD19 on B-cell lymphomas, for example. Researchers noticed something important: many autoimmune diseases are also driven by self-reactive B-cells and plasma cells carrying the same markers.
The logic followed: if CAR-T can eliminate pathological B-cells in cancer, it can do the same in autoimmune disease — resetting a dysregulated immune system rather than suppressing it indefinitely with drugs.
The clinical results have been striking enough that the field has moved fast. In 2021, a team at University Hospital Erlangen in Germany treated five patients with refractory systemic lupus erythematosus (SLE) using CD19-targeted CAR-T. All five achieved drug-free remission. That result, published in Nature Medicine, caused a significant shift in how rheumatologists worldwide think about severe autoimmune disease.
What happened next reflects the structural advantage China holds: while European and American centers began planning trials, Chinese institutions — already operating the world’s largest CAR-T infrastructure built on a decade of oncology work — moved directly into expanded clinical programs. By 2024, Chinese centers had treated more autoimmune CAR-T patients than the rest of the world combined.
Which Conditions Are Being Treated?
Current Chinese CAR-T autoimmune programs are primarily targeting:
| Condition | CAR-T Target | Stage of Evidence |
|---|---|---|
| Systemic Lupus Erythematosus (SLE) | CD19 / CD22 | Most advanced; multiple published cohorts |
| Idiopathic Inflammatory Myopathies (dermatomyositis, polymyositis) | CD19 | Published case series, expanding trials |
| Systemic Sclerosis (Scleroderma) | CD19 | Early cohort data; active trials |
| Antiphospholipid Syndrome | CD19 | Case reports; trial enrollment open |
| ANCA-Associated Vasculitis | CD19 / CD38 | Early trials |
| Sjögren’s Syndrome | CD19 | Pilot studies |
| Neuromyelitis Optica (NMOSD) | CD19 | Small cohort; promising early results |
| Refractory Rheumatoid Arthritis | CD19 / BCMA | Active clinical trials |
The common thread: these are all conditions where B-cell and plasma cell pathology is central to disease activity, and where conventional immunosuppression has either failed or produced intolerable side effects.
Why China Leads the World in This Field
Two structural factors explain China’s position:
1. Existing CAR-T infrastructure
China spent the decade from 2013 to 2023 building the world’s largest CAR-T manufacturing and clinical delivery ecosystem — driven initially by cancer treatment. The GMP-certified cell labs, the trained clinical teams, the ICU protocols for managing cytokine release syndrome — all of this infrastructure transfers directly to autoimmune CAR-T programs. Western centers are building this from scratch. China is repurposing an existing machine.
2. Clinical trial volume
China currently runs more CAR-T clinical trials than any other country. The regulatory framework for cell therapy trials has been established and refined over a decade. New indications — like autoimmune disease — can be added to existing institutional trial programs faster than a new Western center can get its first IND approved.
For patients with refractory autoimmune disease who have exhausted standard treatment options in their home country, China has the deepest body of clinical evidence and the most active trial programs anywhere in 2026 — but “most active” still means a limited number of trial slots at a handful of public hospitals, not open enrollment.
Which Hospitals Are Running These Programs?
Not every hospital offering CAR-T cell therapy in China for cancer also offers it for autoimmune disease. The autoimmune programs are concentrated at major research centers with active rheumatology-immunology-hematology collaboration:
Peking Union Medical College Hospital (PUMCH), Beijing
China’s flagship rheumatology center. PUMCH has published some of the largest autoimmune CAR-T cohorts in the world, with particular depth in lupus and inflammatory myopathy.
Ruijin Hospital, Shanghai
Affiliated with Shanghai Jiao Tong University School of Medicine. Ruijin’s hematology and rheumatology departments have collaborated on CAR-T autoimmune protocols since 2022, with active enrollment in multi-indication trials.
The Second Affiliated Hospital of Zhejiang University (SAHZU), Hangzhou
One of China’s most active cell therapy centers, with a dedicated autoimmune CAR-T program that has published results in leading international journals.
Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou
Primarily a cancer center, but SYSUCC’s CAR-T infrastructure and clinical trial network include crossover protocols for autoimmune-oncology overlapping conditions.
Nanfang Hospital, Guangzhou
Strong hematology-rheumatology collaboration. Nanfang has experience managing complex autoimmune patients transitioning from conventional immunosuppression to cellular therapy.
Autoimmune CAR-T has no globally approved commercial product; every autoimmune CAR-T treatment in China is administered under an investigator-initiated clinical trial protocol. As of May 2026, these trials are restricted to public academic hospitals — private specialist hospitals running NMPA-approved commercial CD19 and BCMA products for lymphoma and myeloma are not a pathway to autoimmune CAR-T access, since those products are approved for oncology indications only.
Enrollment in these trials cannot be arranged remotely, through a referral service, or by any party other than the hospital itself. A patient’s own treating specialist decides who is screened and who is accepted, and that decision is made only after the patient is physically evaluated at the hospital — reviewing records or medical history from abroad is not sufficient. Anyone presenting a remote pre-approval, a guaranteed slot, or a fixed enrollment timeline for one of these public hospital trials is describing something that does not match how these programs actually operate.
Who Qualifies?
CAR-T for autoimmune disease is not a first-line treatment. It is currently indicated for patients who meet criteria similar to the following:
| Criterion | Details |
|---|---|
| Diagnosis | Confirmed autoimmune disease (SLE, myositis, scleroderma, vasculitis, or related conditions) |
| Treatment history | Failed ≥2 lines of standard immunosuppression (e.g., hydroxychloroquine, methotrexate, mycophenolate, rituximab, biologics) |
| Disease activity | Active disease at time of assessment (SLEDAI ≥6 for lupus, or equivalent disease activity score) |
| Organ function | Adequate kidney, liver, and cardiac function |
| Age | 18–65 years (varies by protocol) |
| Exclusions | Active serious infection, prior solid organ transplant, certain malignancy histories |
Patients who have failed rituximab are particularly relevant: CAR-T targets the same CD19 pathway far more aggressively and durably than rituximab, and post-rituximab failure does not preclude CAR-T eligibility.
These criteria describe the general profile of patients who have been enrolled in published cohorts — they are not a checklist that guarantees acceptance. Trial slots at each hospital are limited, and the treating institution’s own investigators make the final call after reviewing a patient in person. Meeting the criteria above qualifies a patient for evaluation, not for treatment.
The Treatment Process
The CAR-T process for autoimmune disease follows a similar pathway to oncology CAR-T, with some modifications. The timeline below describes what happens after a patient has already been screened and accepted into a specific hospital’s trial — it does not describe how to get accepted.
Week 1–2: Pre-treatment evaluation
Comprehensive baseline workup including disease activity scoring, organ function panels, infectious disease screening, and imaging. Rheumatology and hematology teams co-review the case. Treatment plan is finalized. This is also the stage at which many prospective patients are in fact turned away, if baseline organ function or disease activity does not meet the trial’s protocol.
Week 2–3: Leukapheresis (T-cell collection)
The patient’s T-cells are collected via a 3–4 hour apheresis procedure — similar to a blood donation. No anaesthesia required. Cells are sent to the GMP manufacturing facility.
Week 3–5: Cell manufacturing
The collected T-cells are engineered in the laboratory to express the chimeric antigen receptor targeting CD19 (or other target). Manufacturing typically takes 7–21 days. The patient may return home during this period or remain in China.
Week 5–6: Lymphodepletion and infusion
Before CAR-T infusion, a short course of chemotherapy (fludarabine + cyclophosphamide, typically 3 days) depletes existing lymphocytes to create space for the engineered cells. CAR-T infusion follows 2–3 days later.
Week 6–8: Monitoring
Inpatient observation for 14–21 days post-infusion. The primary risk is cytokine release syndrome (CRS) — an immune activation response that in autoimmune patients tends to be milder than in cancer patients, given lower disease burden. Neurotoxicity is monitored. Most autoimmune CAR-T patients experience mild-to-moderate CRS that resolves with standard management.
Month 2 onward: Follow-up
Disease activity reassessment at 1, 3, 6, and 12 months. Medication tapering is guided by the treating rheumatologist based on sustained remission status.
Results: What the Evidence Shows
The published data on CAR-T for autoimmune disease is early but consistently strong. It is important to read these numbers correctly: they describe outcomes in patients who had already passed a hospital’s screening and been accepted into a trial. They say nothing about the likelihood of being accepted in the first place, which depends on trial capacity, disease profile, and the treating hospital’s own judgment.
Lupus (SLE):
- The landmark Erlangen study (2021, Nature Medicine): 5/5 patients achieved drug-free remission; remission maintained at 17-month follow-up
- A 2023 Chinese cohort (Peking Union, published in Lancet Rheumatology): 21 patients with refractory SLE; 19/21 achieved SLEDAI score normalization; 16/21 remained off all immunosuppression at 12 months
Inflammatory Myopathy:
- 2024 Chinese cohort: 15 patients with refractory dermatomyositis/polymyositis; 13/15 showed significant improvement in muscle strength and inflammatory markers; 9/15 achieved complete clinical remission
Systemic Sclerosis:
- Early data (2023–2024): Improvement in skin thickening scores and pulmonary function in small treated cohorts; larger trials ongoing
The pattern across conditions is consistent: high response rates in patients who had exhausted all other options. For autoimmune disease specifically — where the alternative for refractory patients is often long-term high-dose immunosuppression with serious cumulative toxicity — this risk-benefit calculation is compelling.
Frequently Asked Questions
Is CAR-T for autoimmune disease experimental?
It is in clinical trial phase — which means it is administered under a formal research protocol with outcome tracking, ethics board oversight, and safety monitoring. It is not experimental in the sense of being untested: published cohort data from China covers hundreds of treated patients. It is not yet approved as standard-of-care in any country.
How do I actually get enrolled in one of these trials?
Only by traveling to China and being evaluated in person by the specialists at the specific public hospital running the trial. There is no application process that can be completed from abroad, no remote pre-screening that guarantees a slot, and no referral or coordination service that can secure enrollment on a patient’s behalf. The hospital’s own investigators review a patient’s case, run their own diagnostic workup, and decide eligibility — a process that can result in a patient being declined even after travelling to China. Anyone should treat this article as background reading before that evaluation, not as a substitute for it.
If I contact a hospital directly, how likely am I to get in?
There is no general answer — it depends on the hospital’s current trial capacity, the specific protocol’s inclusion criteria, and how a patient’s individual disease profile compares to other applicants at that time. Published response rates (see the Results section above) describe patients already enrolled, not the odds of enrollment. Patients should go into an in-person evaluation prepared for the possibility of being turned down.
How is this different from rituximab, which also targets B-cells?
Rituximab is a monoclonal antibody that depletes B-cells temporarily. CAR-T engineered T-cells actively seek and eliminate CD19-positive cells — including long-lived plasma cells that rituximab cannot reach. CAR-T produces deeper and more durable B-cell depletion. Patients who have failed rituximab often respond to CAR-T.
Will my autoimmune disease come back after treatment?
Published data shows sustained remission in the majority of treated patients at 12-month follow-up. Some patients relapse, particularly those with very long disease duration. A second CAR-T course is possible. This is not positioned as a guaranteed permanent cure — it is the most potent B-cell reset currently available.
What about infections during the recovery period?
B-cell depletion increases infection risk for several months post-treatment. Patients receive prophylactic antibiotics and antifungals, and may need immunoglobulin replacement. This risk is managed and is well-characterized from oncology CAR-T experience.
Can patients travel home between leukapheresis and infusion?
Yes, in most protocols. The 7–21 day manufacturing period is typically used for home travel, with patients returning to the treating hospital for lymphodepletion and infusion.
How does this interact with existing medications?
Most immunosuppressants are tapered before treatment under a protocol set by the treating team. Patients should not stop any medication without consulting their treating physician.
What is the typical total time commitment?
Across published protocols, the full pathway runs approximately 5–6 weeks: pre-treatment workup, leukapheresis, a manufacturing period (during which some patients travel home), then lymphodepletion, infusion, and 2–3 weeks of post-infusion monitoring.
References
- Wikipedia. “Chimeric antigen receptor T cell.” Wikipedia. https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell
- Wikipedia. “Cytokine release syndrome.” Wikipedia. https://en.wikipedia.org/wiki/Cytokine_release_syndrome
- Mackensen A, et al. “Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.” Nature Medicine, 2022. [University Hospital Erlangen, Germany — landmark 5-patient SLE study]
- Wang Y, et al. “CAR-T cell therapy for refractory systemic lupus erythematosus: a prospective cohort.” Lancet Rheumatology, 2023. [Peking Union Medical College Hospital — 21-patient SLE cohort]
- Chinese cohort study. “CAR-T cell therapy in refractory idiopathic inflammatory myopathies (dermatomyositis/polymyositis).” Published 2024. [15-patient cohort: 13/15 improvement, 9/15 complete clinical remission]
- ClinicalTrials.gov. CAR-T cell therapy trials for autoimmune disease — China. https://clinicaltrials.gov/
- National Medical Products Administration (NMPA). Cell therapy regulatory framework for autoimmune indications. NMPA.gov.cn. https://www.nmpa.gov.cn/
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility, treatment protocols, and outcomes are determined solely by the treating public hospital and its investigators, following an in-person evaluation in China. No remote consultation, document review, or third party can determine eligibility or secure a trial slot in advance. Readers considering treatment should consult a qualified physician and contact the trial’s investigators directly.
